文献速递毛发、甲与色素性疾病

DPP4抑制促进毛囊活化与再生的研究

Repurposing DPP4 Inhibition to Improve Hair Follicle Activation and Regeneration.
PubMed 文献 · J Invest Dermatol · 2023-05-24

研究显示DPP4在毛囊生长停滞、毛囊丢失及非再生性创面区域过表达。局部外用FDA/EMA批准的西格列汀在鼠毛囊活化/再生临床前模型中加速生长期进程,创面治疗减少纤维化标志物、增加创周生长期诱导并促进创面中心毛囊再生。这些效应与Wnt靶点Lef1表达升高相关。

要点

  • DPP4在毛囊生长停滞、毛囊丢失及非再生性创面区域过表达。
  • 局部西格列汀加速小鼠毛囊生长期进程并促进创面毛囊再生。
  • 效应伴随Wnt靶点Lef1表达升高。

核心结论

  • DPP4在毛囊生物学中起作用,局部DPP4抑制可能逆转脱发及损伤后的毛囊丢失。

研究设计与样本

  • 研究在小鼠皮肤和人类头皮的毛囊生长停滞、毛囊丢失及非再生性创面区域检测DPP4表达,并在小鼠毛囊活化/再生及创面临床前模型中局部外用西格列汀。

主要发现

  • DPP4在毛囊生长停滞(休止期)、毛囊丢失及非再生性创面区域过表达。
  • 局部西格列汀加速小鼠毛囊生长期进程。
  • 西格列汀治疗创面减少纤维化标志物表达、增加创周生长期诱导并促进创面中心毛囊再生。
  • 上述效应与Wnt靶点Lef1表达升高相关。
  • 西格列汀降低皮肤促纤维化信号、诱导毛囊细胞分化轨迹并激活与毛囊活化/生长相关的Wnt靶点而非支持纤维化的靶点。

临床怎么用

  • 西格列汀目前作为口服药物治疗糖尿病,研究提示其可能被重新定位为局部治疗药物以逆转脱发及损伤后的毛囊丢失。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Skin injury and several diseases elicit fibrosis and induce hair follicle (HF) growth arrest and loss. The resulting alopecia and disfiguration represent a severe burden for patients, both physically and psychologically. Reduction of profibrotic factors such as dipeptidyl peptidase 4 (DPP4) might be a strategy to tackle this issue. We show DPP4 overrepresentation in settings with HF growth arrest (telogen), HF loss, and nonregenerative wound areas in mouse skin and human scalp. Topical DPP4 inhibition with Food and Drug Administration/European Medicines Agency-approved sitagliptin on preclinical models of murine HF activation/regeneration results in accelerated anagen progress, whereas treatment of wounds with sitagliptin results in reduced expression of fibrosis markers, increased induction of anagen around wounds, and HF regeneration in the wound center. These effects are associated with higher expression of Wnt target Lef1, known to be required for HF anagen/HF-activation and regeneration. Sitagliptin treatment decreases profibrotic signaling in the skin, induces a differentiation trajectory of HF cells, and activates Wnt targets related to HF activation/growth but not those supporting fibrosis. Taken together, our study shows a role for DPP4 in HF biology and shows how DPP4 inhibition, currently used as oral medication to treat diabetes, could be repurposed into a topical treatment agent to potentially reverse HF loss in alopecia and after injury.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Helm M, Schmidt M, Del Duca E, et al. Repurposing DPP4 Inhibition to Improve Hair Follicle Activation and Regeneration. J Invest Dermatol. 2023. PMID: 37236597. doi:10.1016/j.jid.2023.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。